Literature DB >> 22328834

egfr tyrosine kinase inhibitors in lung cancer: make no assumptions.

B Melosky.   

Abstract

Entities:  

Year:  2012        PMID： 22328834      PMCID： PMC3267582          DOI： 10.3747/co.19.955

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  3 in total

1.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

Authors:  Federico Cappuzzo; Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Aleksandra Szczésna; Erzsébet Juhász; Emilio Esteban; Olivier Molinier; Wolfram Brugger; Ivan Melezínek; Gaëlle Klingelschmitt; Barbara Klughammer; Giuseppe Giaccone
Journal:  Lancet Oncol       Date:  2010-05-20       Impact factor: 41.316

2.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

3.  Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

Authors:  Jean-Yves Douillard; Frances A Shepherd; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Mei-Lin Liao; Helge Bischoff; Martin Reck; Mark V Sellers; Claire L Watkins; Georgina Speake; Alison A Armour; Edward S Kim
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.